美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

羅文

10.93

0.0000

成交量：- -

成交額：- -

市值：13.91億

市盈率：-3.99

高：10.93

開：10.93

低：10.93

收：10.93

資料載入中...

總覽公司新聞公告

國務院反壟斷反不正當競爭委員會專家諮詢組召開2025年全體會議

羅文在寧夏調研市場監管領域深化羣眾身邊不正之風和腐敗問題集中整治工作

中国质量新闻网

羅文在寧夏調研市場監管領域深化羣眾身邊不正之風和腐敗問題集中整治工作

中国质量新闻网

深交所2025全球投資者大會5月19日至20日在深圳舉行

國家市場監管總局局長羅文：自覺抵制低價傾銷、互黑互踩

智通财经网

市場監管總局局長羅文：綜合整治“內卷式”競爭，維護公平競爭市場秩序

市場監管總局：提出一批可實施、可落地的重大基礎設施建設項目和信息化建設項目

全球首個零輻射核藥研發生產基地蓄勢待發，遠大醫藥創新產品管線夯實核藥國際領軍地位

股價大漲15%！遠大醫藥(00512)全球核藥龍頭地位再夯實又一RDC治療產品邁入國際多中心III期臨牀

【遠大醫藥(00512.HK)全球創新放射性核素偶聯藥物 TLX591 加入國際多中心 III 期臨牀試驗的申請已獲中國藥監局受理】遠大醫藥(00512.HK)公佈，該集團用於治療前列腺癌的全球創新放射性核素偶聯藥物(RDC) TLX591 (177Lu- HuJ591)加入國際多中心 III 期臨牀試驗的申請，近日已獲得中華人民共和國國家藥品監督管理局正式受理，這是集團在覈藥抗腫瘤診療領域的重要研發進展。該集團高度重視核藥產業全球化發展戰略，積極推進創新核藥產品的全球化開發及註冊進程，並將持續深化集團核藥產品管線的全球化拓展。

健訊Daily | 國家衞健委：無資質機構嚴禁開展產前篩查；遠大醫藥GPC-3靶向RDC臨牀數據全球首發

21世纪经济报道

遠大醫藥：全球創新RDC藥物GPN02006研發迎來新突破

每日经济新闻

遠大醫藥：全球創新RDC藥物GPN02006研發迎來新突破

全球創新GPC-3靶向RDC臨牀突破！遠大醫藥(00512)破解中國肝癌早診難題，劍指肝癌精準診療百億藍海

智通财经网

核藥龍頭傳利好，遠大醫藥(00512)全球創新RDC再獲研發進展，或提供腦膠質瘤治療新選擇

國台辦：大陸經濟前景好不好事實最有説服力

Bitget鏈上交易（Onchain）上線項目NO、RDC

科倫藥業(002422.SZ)：子公司放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲批准

科倫藥業(002422.SZ)：放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲批

科倫博泰生物-B(06990)：放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲國家藥品監督管理局批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RDC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RDC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDC\",,,,,undefined,":{"symbol":"RDC","market":"US","secType":"STK","nameCN":"羅文","latestPrice":10.93,"timestamp":1575925200000,"preClose":10.93,"halted":4,"volume":0,"delay":0,"floatShares":105959169,"shares":127294643,"eps":-2.74,"marketStatus":"退市","change":0,"latestTime":"05-29 09:57:32 EDT","open":10.93,"high":10.93,"low":10.93,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.74,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1748548800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-73684800000,"exchange":"NYSE","adjPreClose":10.93,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDC\",,,,,undefined,":{"symbol":"RDC","floatShares":105959169,"roa":"--","roe":"--","lyrEps":-2.737588,"shares":127294643,"dividePrice":0,"high":10.93,"amplitude":0,"preClose":10.93,"low":10.93,"week52Low":7.77,"pbRate":"0.28","week52High":20.87,"institutionHeld":0.8565,"latestPrice":10.93,"eps":-2.74,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.74,"open":10.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RDC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538345867","title":"國務院反壟斷反不正當競爭委員會專家諮詢組召開2025年全體會議","url":"https://stock-news.laohu8.com/highlight/detail?id=2538345867","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538345867?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 16:20","pubTimestamp":1748334021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["RDC"],"gpt_icon":0},{"id":"2538623433","title":"羅文在寧夏調研市場監管領域深化羣眾身邊不正之風和腐敗問題集中整治工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2538623433","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538623433?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 11:16","pubTimestamp":1748315760,"startTime":"0","endTime":"0","summary":"罗文强调，全系统要扎实推进深化群众身边不正之风和腐败问题集中整治工作，加强民用“三表”计量监督管理，健全生产、检定、使用全链条监管机制，督促公用企业落实主体责任，规范价格收费行为，严格执行国家规定的价格优惠政策，依法严厉打击计量作弊、不执行政府定价等违法违规行为，维护人民群众切身利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-27/doc-inexymnk9133532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RDC"],"gpt_icon":0},{"id":"2537413795","title":"羅文在寧夏調研市場監管領域深化羣眾身邊不正之風和腐敗問題集中整治工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2537413795","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537413795?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 22:07","pubTimestamp":1748009220,"startTime":"0","endTime":"0","summary":"转自：市场监管总局网站5月20日至22日，市场监管总局党组书记、局长罗文在宁夏调研市场监管领域深化群众身边不正之风和腐败问题集中整治工作。调研组随机抽取银川市、吴忠市的供水、供电、供气公用企业和计量检定机构等，现场调研水电气价格收费情况，以及民用“三表”检定、轮换情况，并对发现的问题进行督促整改。总局相关司局同志参加调研。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-23/doc-inexqnpu5795357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RDC"],"gpt_icon":0},{"id":"2536871549","title":"深交所2025全球投資者大會5月19日至20日在深圳舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2536871549","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536871549?lang=zh_tw&edition=fundamental","pubTime":"2025-05-19 09:20","pubTimestamp":1747617605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SG9999006266.SGD","FSTM.SI","ES3.SI","SGXZ27511609.SGD","LU0898667661.SGD","LU2242646235.USD","RDC","LU0205439572.USD","LU0326948709.USD","LU0877626530.USD","LU0192582467.USD","161123","LU2242652126.USD","SG9999014492.USD","SG9999001135.SGD","SG9999004360.SGD","SG9999016042.SGD","LU1920062954.HKD","LU2242646821.SGD","LU0831103253.SGD","BK6516","LU2401740654.USD","S68.SI","LU1119993845.HKD","BK6033","SG9999001846.SGD","STI.SI","BK6523","161631","LU0188438112.USD","LU1920063259.USD","SG9999003826.SGD","SG9999000343.SGD","FSTAS.SI","162414","SG9999014484.SGD","399300","159982"],"gpt_icon":0},{"id":"2535507273","title":"國家市場監管總局局長羅文：自覺抵制低價傾銷、互黑互踩","url":"https://stock-news.laohu8.com/highlight/detail?id=2535507273","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535507273?lang=zh_tw&edition=fundamental","pubTime":"2025-05-16 16:21","pubTimestamp":1747383660,"startTime":"0","endTime":"0","summary":"继5月13日五部门联合约谈京东、美团、饿了么三家外卖平台后，国家市场监督管理总局党组书记、局长罗文16日在《人民日报》发表署名文章，再次强调要综合治理“内卷式竞争”问题。罗文在文章中提出，需要坚决遏制不正之风，依法查处不正当竞争和价格违法行为。此外，罗文也在文章中提出，要积极推动行业加强自律依法竞争，指导行业协会依法自律，自觉抵制低价倾销、互黑互踩等乱象。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2025-05-16/doc-inewtxve6186422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RDC"],"gpt_icon":0},{"id":"2535804718","title":"市場監管總局局長羅文：綜合整治“內卷式”競爭，維護公平競爭市場秩序","url":"https://stock-news.laohu8.com/highlight/detail?id=2535804718","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535804718?lang=zh_tw&edition=fundamental","pubTime":"2025-05-16 07:37","pubTimestamp":1747352229,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["RDC"],"gpt_icon":0},{"id":"2535776487","title":"市場監管總局：提出一批可實施、可落地的重大基礎設施建設項目和信息化建設項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2535776487","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535776487?lang=zh_tw&edition=fundamental","pubTime":"2025-05-13 21:15","pubTimestamp":1747142110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["RDC"],"gpt_icon":0},{"id":"2533183719","title":"全球首個零輻射核藥研發生產基地蓄勢待發，遠大醫藥創新產品管線夯實核藥國際領軍地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183719","media":"新浪医药","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183719?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 08:46","pubTimestamp":1746665181,"startTime":"0","endTime":"0","summary":"远大医药目前是拥有进入中国III期临床研究中诊断和治疗类RDC创新药总计储备最多的企业，也是全球范围内在核药抗肿瘤领域拥有最丰富产品管线和诊疗一体化布局的创新药企之一，是名副其实的全球核药领军企业。值得注意的是，远大医药用于诊断前列腺癌的全球创新RDC产品TLX591-CDx计划于今年二季度完成中国III期临床的全部患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508085210a475fb05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508085210a475fb05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX","RDC","BK4139"],"gpt_icon":0},{"id":"2533693938","title":"股價大漲15%！遠大醫藥(00512)全球核藥龍頭地位再夯實 又一RDC治療產品邁入國際多中心III期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2533693938","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533693938?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:53","pubTimestamp":1746622387,"startTime":"0","endTime":"0","summary":"当日晚间，公司再度传来捷报，其用于治疗前列腺癌的全球创新放射性核素偶联药物 TLX591 加入国际多中心III期临床试验的申请已获得国家药监局正式受理。目前，远大医药在核药抗肿瘤诊疗板块已有4款RDC创新药获批开展注册性临床研究，其中3款已进入III期临床阶段。值得注意的是，远大医药用于诊断前列腺癌的全球创新RDC产品TLX591-CDx计划于今年二季度完成中国III期临床的全部患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RDC","00512","BK4134","III","BK1191"],"gpt_icon":0},{"id":"2533893329","title":"【遠大醫藥(00512.HK)全球創新放射性核素偶聯藥物 TLX591 加入國際多中心 III 期臨牀試驗的申請已獲中國藥監局受理】遠大醫藥(00512.HK)公佈，該集團用於治療前列腺癌的全球創新放射性核素偶聯藥物(RDC) TLX591 (177Lu- HuJ591)加入國際多中心 III 期臨牀試驗的申請，近日已獲得中華人民共和國國家藥品監督管理局正式受理，這是集團在覈藥抗腫瘤診療領域的重要研發進展。該集團高度重視核藥產業全球化發展戰略，積極推進創新核藥產品的全球化開發及註冊進程，並將持續深化集團核藥產品管線的全球化拓展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533893329","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533893329?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:28","pubTimestamp":1746617287,"startTime":"0","endTime":"0","summary":"远大医药(00512.HK)公布，该集团用于治疗前列腺癌的全球创新放射性核素偶联药物(RDC) TLX591 (177Lu- HuJ591)加入国际多中心 III 期临床试验的申请，近日已获得中华人民共和国国家药品监督管理局正式受理，这是集团在核药抗肿瘤诊疗领域的重要研发进展。该集团高度重视核药产业全球化发展战略，积极推进创新核药产品的全球化开发及注册进程，并将持续深化集团核药产品管线的全球化拓展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07192850202626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","00512","BK4134","BK1576","03347","BK1583","BK1191","RDC","III"],"gpt_icon":0},{"id":"2529735013","title":"健訊Daily | 國家衞健委：無資質機構嚴禁開展產前篩查；遠大醫藥GPC-3靶向RDC臨牀數據全球首發","url":"https://stock-news.laohu8.com/highlight/detail?id=2529735013","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529735013?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 07:31","pubTimestamp":1745278289,"startTime":"0","endTime":"0","summary":"政策动向国家卫健委：无资质机构严禁开展产前筛查4月21日，国家卫健委发布《关于进一步加强产前筛查服务管理的通知》，明确医疗机构开展产前筛查须经卫健行政部门许可，从业人员必须通过专业考核并取得相应资质证书。无资质机构及人员严禁开展相关服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504223383542290.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504223383542290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00512","GPC","LU2237443978.SGD","BK4159","LU2237443622.USD","LU2237443549.SGD","BK4588","LU2237443382.USD","BK1191","BK4585","RDC"],"gpt_icon":0},{"id":"2529656805","title":"遠大醫藥：全球創新RDC藥物GPN02006研發迎來新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2529656805","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529656805?lang=zh_tw&edition=fundamental","pubTime":"2025-04-21 20:17","pubTimestamp":1745237844,"startTime":"0","endTime":"0","summary":"每经AI快讯，远大医药公告称，集团合作开发的用于诊断肝细胞癌（HCC）的全球创新放射性核素偶联药物(RDC)GPN02006，在中国开展的研究者发起的临床研究（IIT临床研究），近日取得了里程碑式突破，并于成都2025未来XDC新药大会中公开发表了临床结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504213383222841.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504213383222841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RDC","BK1191","00512"],"gpt_icon":0},{"id":"2529808143","title":"遠大醫藥：全球創新RDC藥物GPN02006研發迎來新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2529808143","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529808143?lang=zh_tw&edition=fundamental","pubTime":"2025-04-21 20:03","pubTimestamp":1745237014,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4006","00512","LU2237443549.SGD","BK4585","BK1191","BK4588","LU2237443622.USD","GPC","LU2237443978.SGD","RDC.AU","HCC","LU2237443382.USD","BK4159","RDC"],"gpt_icon":0},{"id":"2529874382","title":"全球創新GPC-3靶向RDC臨牀突破！遠大醫藥(00512)破解中國肝癌早診難題，劍指肝癌精準診療百億藍海","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874382","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874382?lang=zh_tw&edition=fundamental","pubTime":"2025-04-21 18:52","pubTimestamp":1745232777,"startTime":"0","endTime":"0","summary":"直击肝细胞癌精准诊疗痛点，GPC-3靶向突破领跑全球原发性肝癌中是全球第六大常见癌症和第三大癌症死亡原因。因此，对HCC患者精准诊断和精准治疗，是提高患者预后、降低患者死亡风险的重要手段。此外，针对GPC-3靶点的治疗类RDC产品也已列入公司的研发计划中，有望实现对HCC患者的RDC诊疗一体化。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","GPC","BK4159","LU2237443549.SGD","BK4585","BK4588","LU2237443382.USD","LU2237443622.USD","RDC","LU2237443978.SGD","00512"],"gpt_icon":0},{"id":"2527029923","title":"核藥龍頭傳利好，遠大醫藥(00512)全球創新RDC再獲研發進展，或提供腦膠質瘤治療新選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=2527029923","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527029923?lang=zh_tw&edition=fundamental","pubTime":"2025-04-16 18:42","pubTimestamp":1744800148,"startTime":"0","endTime":"0","summary":"该产品已获FDA孤儿药认定。相比之下，仅接受EBRT治疗的复发性胶质母细胞瘤患者的中位生存期仅为9.9个月。未来若远大医药TLX101开发进展顺利，则有望提供全新的胶质母细胞瘤治疗手段，并为公司提供新的业绩增长点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","RDC","00512"],"gpt_icon":0},{"id":"2527832322","title":"國台辦：大陸經濟前景好不好 事實最有説服力","url":"https://stock-news.laohu8.com/highlight/detail?id=2527832322","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527832322?lang=zh_tw&edition=fundamental","pubTime":"2025-04-16 10:37","pubTimestamp":1744771061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["RDC"],"gpt_icon":0},{"id":"2527156726","title":"Bitget鏈上交易（Onchain）上線項目NO、RDC","url":"https://stock-news.laohu8.com/highlight/detail?id=2527156726","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527156726?lang=zh_tw&edition=fundamental","pubTime":"2025-04-14 19:35","pubTimestamp":1744630550,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 Bitget 链上交易（Onchain）上线项目 NO、RDC，用户在 App 界面进入链上交易板块即可开启交易。\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/427037?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["RDC"],"gpt_icon":0},{"id":"2522027120","title":"科倫藥業(002422.SZ)：子公司放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2522027120","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522027120?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 20:09","pubTimestamp":1742904573,"startTime":"0","endTime":"0","summary":"格隆汇3月25日丨科伦药业公布，公司控股子公司四川科伦博泰生物医药股份有限公司于2023年9月14日公告宣布科伦博泰与西南医科大学附属医院就放射性核素偶联药物SKB107订立独占性许可协议。公司近日获悉，科伦博泰已于2025年3月25日收到国家药品监督管理局药品审评中心批准SKB107新药临床试验申请的临床试验通知书。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/25200949037555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","BK0060","BK1141","BK1583","03347","RDC","LU1064130708.USD","LU1064131003.USD","002422","BK0239","BK1576"],"gpt_icon":0},{"id":"2522022289","title":"科倫藥業(002422.SZ)：放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022289","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022289?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 20:03","pubTimestamp":1742904220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)发布公告，公司近日获悉，科伦博泰已于2025年3月25日收到国家药品监督管理局药品审评中心批准SKB107新药临床试验申请的临床试验通知书。SKB107是由科伦博泰及西南医大附属医院核医学科共同开发的，以小分子作为靶向配体，搭配适宜的连接技术、螯合剂和治疗用放射性同位素而组成的新型RDC药物，拟用于治疗晚期实体瘤骨转移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","LU1064131003.USD","03347","BK1583","BK1141","BK0060","BK1576","LU2148510915.USD","BK0239","RDC","002422"],"gpt_icon":0},{"id":"2522021518","title":"科倫博泰生物-B(06990)：放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021518","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021518?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 19:41","pubTimestamp":1742902872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)公布，公司已于2025年3月25日收到国家药品监督管理局药品审评中心批准SKB107新药临床试验申请的临床试验通知书。SKB107是由公司及西南医大附属医院核医学科共同开发的，以小分子作为靶向配体，搭配适宜的连接技术、螯合剂和治疗用放射性同位素而组成的新型RDC药物，拟用于治疗晚期实体瘤骨转移。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","RDC","03347","BK1141","BK1583","BK1576","06990","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RDC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-27","symbol":"RDC","fiscalQuarterEnding":"2018/12","expectedEps":-1.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-1.11},{"market":"US","date":"2018-10-31","symbol":"RDC","fiscalQuarterEnding":"2018/09","expectedEps":-1.15,"name":null,"time":"盤前","type":"earning","dateTimestamp":1540958400000,"reportTimeType":"pre","actualEps":-1.13},{"market":"US","date":"2018-08-01","symbol":"RDC","fiscalQuarterEnding":"2018/06","expectedEps":-0.93,"name":null,"time":"盤前","type":"earning","dateTimestamp":1533096000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2018-05-01","symbol":"RDC","fiscalQuarterEnding":"2018/03","expectedEps":-0.86,"name":null,"time":"盤前","type":"earning","dateTimestamp":1525147200000,"reportTimeType":"pre","actualEps":-0.89},{"market":"US","date":"2018-02-28","symbol":"RDC","fiscalQuarterEnding":"2017/12","expectedEps":-0.26,"name":null,"time":"盤前","type":"earning","dateTimestamp":1519794000000,"reportTimeType":"pre","actualEps":-0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RDC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RDC\",market:\"US\",delay:false,,,undefined,":{}}}